Abdelgawad HAH, Foster R, Otto M (2024) Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A. Blood Rev 64:101164

Article  PubMed  Google Scholar 

van Leeuwen FHP, van Bergen EDP, Timmer MA, van Vulpen LFD, Schutgens REG, de Jong PA et al (2023) Magnetic resonance imaging evidence for subclinical joint bleeding in a Dutch population of people with severe hemophilia on prophylaxis. J Thromb Haemost 21:1156–1163

Article  PubMed  Google Scholar 

Daffunchio C, Galatro G, Faurlin V, Neme D, Caviglia H (2023) The hidden joint in children with haemophilia on prophylaxis. Thromb Res 226:86–92

Article  PubMed  Google Scholar 

Anderson WF (1990) September 14, 1990: the beginning. Hum Gene Ther: 371–372

Symington E, Rangarajan S, Lester W, Madan B, Pierce GF, Raheja P, Robinson TM, Osmond D, Russell CB, Vettermann C, Agarwal SK, Li M, Wong WY, Laffan M (2024) Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.Haemophilia.;30:320– 30

Coppens M, Pipe SW, Miesbach W, Astermark J, Recht M, van der Valk P et al HOPE-B Investigators Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.Lancet Haematol 2024 M:S2352-3026(24)00006– 1

Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C (2018) Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res 7:15–28

Article  PubMed  Google Scholar 

Riva L, Petrini C (2019) A few ethical issues in translational research for gene and cell therapy. J Transl Med 17:395

Article  PubMed  PubMed Central  Google Scholar 

Pietu G, Giraud N, Chamouard V, Duport G, Lienhart A, Dargaud Y (2024) Perspectives and perception of haemophilia gene therapy by French patients. Haemophilia 30:68–74

Article  PubMed  Google Scholar 

Limjoco J, Calatroni A, Aristizabal P, Thornburg CD (2023) Gene therapy preferences and informed decision-making: Results from a National Hemophilia Foundation Community Voices in research survey. Haemophilia 29:51–60

Article  PubMed  Google Scholar 

Fong S, Yates B, Sihn CR, Mattis AN, Mitchell N, Liu S et al (2022) Inter individual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nat Med 28:789–797

Article  PubMed  PubMed Central  Google Scholar 

Leebeek FWG, Miesbach W (2021) Gene therapy for hemophilia: A review on clinical benefit, limitations, and remaining issues. Blood 138:923–931

Article  PubMed  Google Scholar